United States Biotechnology & Medical Research

Inhibrx Inc (INBX)

Track

Track

Inhibrx Inc. has seen no insider trading activity within the last three months. The most recent transactions occurred in May 2024, involving multiple proposed sales and one direct sell by company officers, including Brendan P. Eckelman and Kelly Deck. These historical filings represent the final recorded movements by corporate leadership.
Ticker: INBX Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Inhibrx Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Sale
Price
156.15
Quantity 99,739 -11.5%
Value US$2,972,701
3.3
THE ECKELMAN LIVING TRUST Officer Officer
Transaction date
Proposed sale
Price
311.13
Quantity 60,550
Value US$1,482,791
3.3
Eckelman Brendan P. Officer Officer
Transaction date
Proposed sale
Price
294.43
Quantity 38,185
Value US$860,179
Deck Kelly Officer Officer
Transaction date
Proposed sale
Price
34.24
Quantity 19,711
Value US$674,905
Deck Kelly Officer Officer
Transaction date
Proposed sale
Price
35.40
Quantity 2,896
Value US$102,518
Deck Kelly Officer Officer
Transaction date
Proposed sale
Price
35.00
Quantity 110
Value US$3,850
Deck Kelly Officer Officer
Transaction date
Proposed sale
Price
35.09
Quantity 3,113
Value US$109,230
Deck Kelly Officer Officer
Transaction date
Proposed sale
Price
35.02
Quantity 16,777
Value US$587,552
Deck Kelly Officer Officer
Transaction date
Proposed sale
Price
35.43
Quantity 32,431
Value US$1,148,999
3.3
Eckelman Brendan P. Officer Officer
Transaction date
Proposed sale
Price
35.33
Quantity 1,898
Value US$67,062
3.3
Eckelman Brendan P. Officer Officer
Transaction date
Proposed sale
Price
35.25
Quantity 24,050
Value US$847,856
3.3
Eckelman Brendan P. Officer Officer
Transaction date
Proposed sale
Price
35.32
Quantity 13,558
Value US$478,827
3.3
Eckelman Brendan P. Officer Officer
Transaction date
Proposed sale
Price
35.75
Quantity 2,150
Value US$76,862
Deck Kelly Officer Officer
Transaction date
Proposed sale
Price
35.75
Quantity 42,523
Value US$1,520,197
Deck Kelly Officer Officer
Transaction date
Proposed sale
Price
35.72
Quantity 10,417
Value US$372,095
Deck Kelly Officer Officer
Transaction date
Proposed sale
Price
35.43
Quantity 62,083
Value US$2,199,363
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
24.71
Quantity 400 -0.0%
Value US$9,883
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
24.20
Quantity 39,600 -1.9%
Value US$958,348
2.5
Lappe Mark Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
25.02
Quantity 60 -0.0%
Value US$1,501
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
25.89
Quantity 1,130 -0.1%
Value US$29,261
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
25.40
Quantity 10,120 -0.5%
Value US$257,094
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
25.66
Quantity 693 -0.0%
Value US$17,780
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
25.08
Quantity 14,608 -0.7%
Value US$366,366
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
24.29
Quantity 13,449 -0.6%
Value US$326,710
2.5
Lappe Mark Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
26.11
Quantity 63 -0.0%
Value US$1,645
2.5
Lappe Mark Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
25.71
Quantity 4,272 -0.2%
Value US$109,833
2.5
Lappe Mark Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
25.36
Quantity 21,665 -0.9%
Value US$549,364
1.5
Kayyem Jon Faiz Non-Executive Director
Transaction date
Planned sale
Price
25.26
Quantity 9,500 -0.3%
Value US$239,999
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
23.99
Quantity 3,003 -0.1%
Value US$72,043
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
23.11
Quantity 4,102 -0.2%
Value US$94,786
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
25.09
Quantity 2,084 -0.1%
Value US$52,293
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
24.36
Quantity 8,598 -0.4%
Value US$209,426
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
23.41
Quantity 22,213 -1.0%
Value US$520,051
1.5
Kayyem Jon Faiz Non-Executive Director
Transaction date
Planned sale
Price
27.61
Quantity 1,959 -0.1%
Value US$54,088
1.5
Kayyem Jon Faiz Non-Executive Director
Transaction date
Planned sale
Price
26.87
Quantity 7,541 -0.2%
Value US$202,591
2.5
Lappe Mark Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
26.29
Quantity 754 -0.0%
Value US$19,820
2.5
Lappe Mark Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
25.53
Quantity 25,246 -1.0%
Value US$644,624
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
28.46
Quantity 1,392 -0.1%
Value US$39,617
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
27.57
Quantity 17,681 -0.8%
Value US$487,493
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
26.83
Quantity 20,927 -1.0%
Value US$561,572
1.5
Kayyem Jon Faiz Non-Executive Director
Transaction date
Planned sale
Price
30.12
Quantity 6,767 -0.2%
Value US$203,819
1.5
Kayyem Jon Faiz Non-Executive Director
Transaction date
Planned sale
Price
29.33
Quantity 2,733 -0.1%
Value US$80,153
2.5
Lappe Mark Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
32.38
Quantity 1,150 -0.0%
Value US$37,241
2.5
Lappe Mark Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
30.67
Quantity 912 -0.0%
Value US$27,969
2.5
Lappe Mark Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
30.15
Quantity 6,773 -0.3%
Value US$204,196
2.5
Lappe Mark Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
28.86
Quantity 1,767 -0.1%
Value US$50,991
2.5
Lappe Mark Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
27.45
Quantity 4,333 -0.2%
Value US$118,937
2.5
Lappe Mark Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
26.57
Quantity 4,106 -0.2%
Value US$109,098
2.5
Lappe Mark Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
25.36
Quantity 6,959 -0.3%
Value US$176,477
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
33.90
Quantity 12,349 -0.6%
Value US$418,641
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
33.34
Quantity 27,651 -1.2%
Value US$921,746
1.5
Kayyem Jon Faiz Non-Executive Director
Transaction date
Planned sale
Price
30.58
Quantity 5,928 -0.2%
Value US$181,255
1.5
Kayyem Jon Faiz Non-Executive Director
Transaction date
Planned sale
Price
29.39
Quantity 3,572 -0.1%
Value US$104,977
2.5
Lappe Mark Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
31.51
Quantity 121 -0.0%
Value US$3,812
2.5
Lappe Mark Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
30.81
Quantity 2,892 -0.1%
Value US$89,090
2.5
Lappe Mark Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
29.92
Quantity 14,006 -0.5%
Value US$419,123
2.5
Lappe Mark Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
28.66
Quantity 8,981 -0.3%
Value US$257,419
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
30.52
Quantity 100 -0.0%
Value US$3,052
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
29.68
Quantity 10,893 -0.5%
Value US$323,302
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
28.97
Quantity 5,954 -0.3%
Value US$172,495
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
27.76
Quantity 4,262 -0.2%
Value US$118,299
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
26.78
Quantity 11,136 -0.5%
Value US$298,182
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
26.06
Quantity 6,207 -0.3%
Value US$161,763
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
24.67
Quantity 1,448 -0.1%
Value US$35,720
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
15.66
Quantity 2,493 -0.1%
Value US$39,032
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
14.86
Quantity 37,507 -1.5%
Value US$557,241
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
18.47
Quantity 15,500 -0.6%
Value US$286,209
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
17.70
Quantity 24,500 -1.0%
Value US$433,626
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
17.17
Quantity 40,000 -1.6%
Value US$686,800
3.3
Eckelman Brendan P. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
25.04
Quantity 400 -0.0%
Value US$10,016
3.3
Eckelman Brendan P. Chief Scientific Officer Executive Director
Transaction date
Planned sale
Price
19.02
Quantity 17,000 -0.7%
Value US$323,340
Wagner Klaus W. Chief Medical Officer Officer
Transaction date
Planned sale
Price
25.29
Quantity 19,559 -8.3%
Value US$494,647
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-05-30 2024-05-28 S Sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
99,739 -11.5%
156.15
US$2,972,701 		99,739 -11.5% 156.15 US$2,972,701
2024-05-28 2024-05-28 PrS Proposed sale
3.3
THE ECKELMAN LIVING TRUST

Officer

Officer
60,550
311.13
US$1,482,791 		60,550 311.13 US$1,482,791
2024-05-22 2024-05-22 PrS Proposed sale
3.3
Eckelman Brendan P.

Officer

Officer
38,185
294.43
US$860,179 		38,185 294.43 US$860,179
2024-05-06 2024-05-06 PrS Proposed sale
Deck Kelly

Officer

Officer
19,711
34.24
US$674,905 		19,711 34.24 US$674,905
2024-03-26 2024-03-26 PrS Proposed sale
Deck Kelly

Officer

Officer
2,896
35.40
US$102,518 		2,896 35.40 US$102,518
2024-03-22 2024-03-22 PrS Proposed sale
Deck Kelly

Officer

Officer
110
35.00
US$3,850 		110 35.00 US$3,850
2024-03-21 2024-03-21 PrS Proposed sale
Deck Kelly

Officer

Officer
3,113
35.09
US$109,230 		3,113 35.09 US$109,230
2024-03-20 2024-03-20 PrS Proposed sale
Deck Kelly

Officer

Officer
16,777
35.02
US$587,552 		16,777 35.02 US$587,552
2024-03-13 2024-03-13 PrS Proposed sale
Deck Kelly

Officer

Officer
32,431
35.43
US$1,148,999 		32,431 35.43 US$1,148,999
2024-03-13 2024-03-13 PrS Proposed sale
3.3
Eckelman Brendan P.

Officer

Officer
1,898
35.33
US$67,062 		1,898 35.33 US$67,062
2024-03-12 2024-03-12 PrS Proposed sale
3.3
Eckelman Brendan P.

Officer

Officer
24,050
35.25
US$847,856 		24,050 35.25 US$847,856
2024-03-11 2024-03-11 PrS Proposed sale
3.3
Eckelman Brendan P.

Officer

Officer
13,558
35.32
US$478,827 		13,558 35.32 US$478,827
2024-03-08 2024-03-08 PrS Proposed sale
3.3
Eckelman Brendan P.

Officer

Officer
2,150
35.75
US$76,862 		2,150 35.75 US$76,862
2024-03-08 2024-03-08 PrS Proposed sale
Deck Kelly

Officer

Officer
42,523
35.75
US$1,520,197 		42,523 35.75 US$1,520,197
2024-03-05 2024-03-05 PrS Proposed sale
Deck Kelly

Officer

Officer
10,417
35.72
US$372,095 		10,417 35.72 US$372,095
2024-03-04 2024-03-04 PrS Proposed sale
Deck Kelly

Officer

Officer
62,083
35.43
US$2,199,363 		62,083 35.43 US$2,199,363
2023-08-30 2023-08-28 B Purchase
3.2
VIKING GLOBAL INVESTORS LP
Large shareholder
511,627 +inf%
19.35
US$9,899,982 		511,627 +inf% 19.35 US$9,899,982
2023-03-02 2023-03-01 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
400 -0.0%
24.71
US$9,883 		400 -0.0% 24.71 US$9,883
2023-03-02 2023-03-01 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
39,600 -1.9%
24.20
US$958,348 		39,600 -1.9% 24.20 US$958,348
2023-03-01 2023-02-28 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
60 -0.0%
25.02
US$1,501 		60 -0.0% 25.02 US$1,501
2023-02-02 2023-02-02 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
1,130 -0.1%
25.89
US$29,261 		1,130 -0.1% 25.89 US$29,261
2023-02-02 2023-02-02 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
10,120 -0.5%
25.40
US$257,094 		10,120 -0.5% 25.40 US$257,094
2023-02-02 2023-02-01 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
693 -0.0%
25.66
US$17,780 		693 -0.0% 25.66 US$17,780
2023-02-02 2023-02-01 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
14,608 -0.7%
25.08
US$366,366 		14,608 -0.7% 25.08 US$366,366
2023-02-02 2023-02-01 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
13,449 -0.6%
24.29
US$326,710 		13,449 -0.6% 24.29 US$326,710
2023-01-24 2023-01-24 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
63 -0.0%
26.11
US$1,645 		63 -0.0% 26.11 US$1,645
2023-01-24 2023-01-24 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
4,272 -0.2%
25.71
US$109,833 		4,272 -0.2% 25.71 US$109,833
2023-01-24 2023-01-23 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
21,665 -0.9%
25.36
US$549,364 		21,665 -0.9% 25.36 US$549,364
2023-01-23 2023-01-23 PlS Planned sale
1.5
Kayyem Jon Faiz
Non-Executive Director
9,500 -0.3%
25.26
US$239,999 		9,500 -0.3% 25.26 US$239,999
2023-01-04 2023-01-04 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
3,003 -0.1%
23.99
US$72,043 		3,003 -0.1% 23.99 US$72,043
2023-01-04 2023-01-04 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
4,102 -0.2%
23.11
US$94,786 		4,102 -0.2% 23.11 US$94,786
2023-01-04 2023-01-03 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
2,084 -0.1%
25.09
US$52,293 		2,084 -0.1% 25.09 US$52,293
2023-01-04 2023-01-03 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
8,598 -0.4%
24.36
US$209,426 		8,598 -0.4% 24.36 US$209,426
2023-01-04 2023-01-03 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
22,213 -1.0%
23.41
US$520,051 		22,213 -1.0% 23.41 US$520,051
2022-12-22 2022-12-21 PlS Planned sale
1.5
Kayyem Jon Faiz
Non-Executive Director
1,959 -0.1%
27.61
US$54,088 		1,959 -0.1% 27.61 US$54,088
2022-12-22 2022-12-21 PlS Planned sale
1.5
Kayyem Jon Faiz
Non-Executive Director
7,541 -0.2%
26.87
US$202,591 		7,541 -0.2% 26.87 US$202,591
2022-12-20 2022-12-19 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
754 -0.0%
26.29
US$19,820 		754 -0.0% 26.29 US$19,820
2022-12-20 2022-12-19 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
25,246 -1.0%
25.53
US$644,624 		25,246 -1.0% 25.53 US$644,624
2022-12-07 2022-12-06 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
1,392 -0.1%
28.46
US$39,617 		1,392 -0.1% 28.46 US$39,617
2022-12-07 2022-12-06 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
17,681 -0.8%
27.57
US$487,493 		17,681 -0.8% 27.57 US$487,493
2022-12-07 2022-12-06 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
20,927 -1.0%
26.83
US$561,572 		20,927 -1.0% 26.83 US$561,572
2022-11-22 2022-11-21 PlS Planned sale
1.5
Kayyem Jon Faiz
Non-Executive Director
6,767 -0.2%
30.12
US$203,819 		6,767 -0.2% 30.12 US$203,819
2022-11-22 2022-11-21 PlS Planned sale
1.5
Kayyem Jon Faiz
Non-Executive Director
2,733 -0.1%
29.33
US$80,153 		2,733 -0.1% 29.33 US$80,153
2022-11-18 2022-11-17 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
1,150 -0.0%
32.38
US$37,241 		1,150 -0.0% 32.38 US$37,241
2022-11-18 2022-11-17 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
912 -0.0%
30.67
US$27,969 		912 -0.0% 30.67 US$27,969
2022-11-18 2022-11-17 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
6,773 -0.3%
30.15
US$204,196 		6,773 -0.3% 30.15 US$204,196
2022-11-18 2022-11-17 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
1,767 -0.1%
28.86
US$50,991 		1,767 -0.1% 28.86 US$50,991
2022-11-18 2022-11-17 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
4,333 -0.2%
27.45
US$118,937 		4,333 -0.2% 27.45 US$118,937
2022-11-18 2022-11-17 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
4,106 -0.2%
26.57
US$109,098 		4,106 -0.2% 26.57 US$109,098
2022-11-18 2022-11-17 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
6,959 -0.3%
25.36
US$176,477 		6,959 -0.3% 25.36 US$176,477
2022-11-02 2022-11-01 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
12,349 -0.6%
33.90
US$418,641 		12,349 -0.6% 33.90 US$418,641
2022-11-02 2022-11-01 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
27,651 -1.2%
33.34
US$921,746 		27,651 -1.2% 33.34 US$921,746
2022-10-24 2022-10-21 PlS Planned sale
1.5
Kayyem Jon Faiz
Non-Executive Director
5,928 -0.2%
30.58
US$181,255 		5,928 -0.2% 30.58 US$181,255
2022-10-24 2022-10-21 PlS Planned sale
1.5
Kayyem Jon Faiz
Non-Executive Director
3,572 -0.1%
29.39
US$104,977 		3,572 -0.1% 29.39 US$104,977
2022-10-18 2022-10-17 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
121 -0.0%
31.51
US$3,812 		121 -0.0% 31.51 US$3,812
2022-10-18 2022-10-17 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
2,892 -0.1%
30.81
US$89,090 		2,892 -0.1% 30.81 US$89,090
2022-10-18 2022-10-17 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
14,006 -0.5%
29.92
US$419,123 		14,006 -0.5% 29.92 US$419,123
2022-10-18 2022-10-17 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
8,981 -0.3%
28.66
US$257,419 		8,981 -0.3% 28.66 US$257,419
2022-10-12 2022-10-07 B Purchase
3.2
VIKING GLOBAL INVESTORS LP
Large shareholder
333,333 +inf%
30.00
US$9,999,957 		333,333 +inf% 30.00 US$9,999,957
2022-10-12 2022-10-07 B Purchase
3.2
VIKING GLOBAL INVESTORS LP
Large shareholder
1,000,000 +70.1%
30.00
US$29,999,900 		1,000,000 +70.1% 30.00 US$29,999,900
2022-10-05 2022-10-04 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
100 -0.0%
30.52
US$3,052 		100 -0.0% 30.52 US$3,052
2022-10-05 2022-10-04 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
10,893 -0.5%
29.68
US$323,302 		10,893 -0.5% 29.68 US$323,302
2022-10-05 2022-10-04 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
5,954 -0.3%
28.97
US$172,495 		5,954 -0.3% 28.97 US$172,495
2022-10-05 2022-10-04 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
4,262 -0.2%
27.76
US$118,299 		4,262 -0.2% 27.76 US$118,299
2022-10-05 2022-10-04 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
11,136 -0.5%
26.78
US$298,182 		11,136 -0.5% 26.78 US$298,182
2022-10-05 2022-10-04 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
6,207 -0.3%
26.06
US$161,763 		6,207 -0.3% 26.06 US$161,763
2022-10-05 2022-10-04 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
1,448 -0.1%
24.67
US$35,720 		1,448 -0.1% 24.67 US$35,720
2022-09-07 2022-09-06 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
2,493 -0.1%
15.66
US$39,032 		2,493 -0.1% 15.66 US$39,032
2022-09-07 2022-09-06 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
37,507 -1.5%
14.86
US$557,241 		37,507 -1.5% 14.86 US$557,241
2022-08-04 2022-08-03 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
15,500 -0.6%
18.47
US$286,209 		15,500 -0.6% 18.47 US$286,209
2022-08-04 2022-08-02 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
24,500 -1.0%
17.70
US$433,626 		24,500 -1.0% 17.70 US$433,626
2022-07-08 2022-07-07 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
40,000 -1.6%
17.17
US$686,800 		40,000 -1.6% 17.17 US$686,800
2022-04-07 2022-04-05 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
400 -0.0%
25.04
US$10,016 		400 -0.0% 25.04 US$10,016
2021-03-24 2021-03-24 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Executive Director
17,000 -0.7%
19.02
US$323,340 		17,000 -0.7% 19.02 US$323,340
2021-02-18 2021-02-17 PlS Planned sale
Wagner Klaus W.

Chief Medical Officer

Officer
19,559 -8.3%
25.29
US$494,647 		19,559 -8.3% 25.29 US$494,647
Explore more

More insider trading research around Inhibrx Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America